Specialised respiratory
Access educational and practical resources designed to support the severe respiratory multidisciplinary team. It is focused on disease education and is intended for UK healthcare professionals.
Welcome
This specialised respiratory site features a range of educational and practical resources intended for healthcare professionals across the spectrum of severe asthma care, including general practitioners, nurses, pharmacists, and other members of the severe respiratory multidisciplinary team. It is designed to help you to broaden your understanding of the latest evidence on the severe asthma treatment pathway as well as other conditions such as chronic rhinosinusitis with nasal polyps (CRSwNP).
Severe asthma and CRSwNP
The severe asthma and CRSwNP resource site features a range of educational and practical resources intended for healthcare professionals working across the spectrum of severe asthma care, including general practitioners, nurses, pharmacists and other members of the severe asthma multidisciplinary team, and is designed to help you as you broaden your understanding of the latest evidence on the severe asthma treatment pathway and common complications of the condition.
Resources include videos from expert clinicians, summary infographics on remission and CPD accredited resources
Prevalence of severe asthma globally and in the United Kingdom
Oral corticosteroid (OCS) burden
The overuse of OCS continues despite growing evidence in the literature demonstrating the detrimental long-term adverse effects associated with even a short-term, low-dose course of OCS in severe asthma patients.5
There is an urgent need for a system-wide severe asthma guideline to help shift away from inappropriate OCS use and to enable primary and secondary care clinicians to confidently recognise and refer people with suspected severe asthma.
Explore the OCS burden page to view educational material developed following a GSK-led event: "OCS Uncovered" a collaborative and systematic effort with expert clinicians and patients to generate a series of initiatives to protect patients with severe asthma from inappropriate OCS use.
IL-5 and severe asthma
As one of the key cytokines involved in severe asthma, IL-5 is responsible for the activation and migration of eosinophils into the airways. However, it also has impacts on other cell types across the immune response.10
Exploring the role of IL-5 in type 2 inflammation is vital for understanding how this complex disease pathophysiology manifests in patients, and how targeting IL-5 can help patients control their asthma more effectively.
Explore our page on the role of IL-5 to learn its effects across the upper and lower airways.
Abbreviations
References
- Asthma+Lung UK. Do No Harm report 2023. Available at: https://www.asthmaandlung.org.uk/sites/default/files/2023-03/severe-asthma_report_final.pdf. Accessed March 2025.
- WHO. Global Asthma Report 2022. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. Accessed March 2025.
- Reddel HK et al. Eur Respir J. 2022;59:2102730.
- Royal College of Physicians. Why asthma still kills. Available at: https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills. Accessed March 2025.
- Price DB et al. J Allergy Asthma 2018;11:193–204.
- WHO. Global Asthma Report 2022. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_ 2022.pdf. Accessed May 2025.
- Reddel HK et al. Eur Respir J. 2022;59:2102730.
- Asthma+Lung UK. Do No Harm report 2023. Available at: https://www.asthmaandlung.org.uk/sites/default/files/2023-03/severe-asthma_report_final.pdf. Accessed May 2025.
- Royal College of Physicians. Why asthma still kills. Available at: https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills. Accessed May 2025.
- Pelaia C, et al. Front Physiol. 2019;10:154.
July 2025 | NP-GB-ASU-WCNT-250001 (V3.0)